MetaSight Diagnostics focuses on advancing non-invasive diagnostic technologies, particularly through the use of liquid biopsy. Their mission is to enhance patient care by providing accurate, affordable, and accessible diagnostic solutions that can be applied on a population scale. Unlike traditional genomic-based liquid biopsies, which are often limited to oncology and can be prohibitively expensive, MetaSight's approach aims to develop a single blood test that can effectively diagnose, monitor, and provide prognostic information for a wide range of diseases.

The company utilizes a proprietary platform that integrates a comprehensive clinico multi-OMICS database, which includes metabolomics, lipidomics, and proteomics. This innovative technology allows for the unbiased analysis of biological samples, enabling the identification of disease markers that can lead to improved diagnostic accuracy. By harnessing these advanced methodologies, MetaSight Diagnostics is positioned to transform the landscape of disease detection and management, making it more accessible to diverse populations.

Israel

MetaSight Diagnostics, a health technology company, is on a mission to create affordable and precise liquid biopsy diagnostics for early detection of a variety of chronic and acute diseases, utilizing proprietary, cost-effective mass spectrometry technologies (metabolomics, lipidomics and proteomics). 

The company has created the world’s largest and most comprehensive serum metabolomics dataset linked with Electronic Health Records and is pursuing additional omics. This unprecedented platform is used by MetaSight’s team of experts in analytical chemistry, AI, and medicine to develop and commercialize diagnostic products to improve human health. 

MetaSight Diagnostics

Company Details